专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20220288205A1 HOMEOPATHIC COMPLEX 有权
公开(公告)号：US20220288205A1
公开(公告)日：2022-09-15
申请号：US17704302
申请日：2022-03-25
申请人： Daniel Farrington , Thomas Farrington
发明人： Daniel Farrington , Thomas Farrington
IPC分类号： A61K41/00 , A61K33/00 , A61K33/04 , A61K33/06 , A61K33/28 , A61K35/02 , A61K35/58 , A61K35/646 , A61K36/185 , A61K45/06 , A61K35/583
摘要： The present invention is directed to a homeopathic complex for use in the treatment of various diseases or disorders, including use as an anti-infective agent and/or in the regeneration of diseased or damaged tissue. Ideally, the anti-infective homeopathic complex of the invention may comprise a homeopathic tincture or dilutions thereof of Hepar sulphuris calcareum or other similar profiled Calcarea or Sulphur salt or acid, Lachesis muta or other remedy with a similar profile, Mercurius Solubilis or similar mercury containing remedy and Silica or other silica containing compounds.

2. 发明授权

US11298421B2 Homeopathic complex 有权
公开(公告)号：US11298421B2
公开(公告)日：2022-04-12
申请号：US16367465
申请日：2019-03-28
申请人： Daniel Farrington , Thomas Farrington
发明人： Daniel Farrington , Thomas Farrington
IPC分类号： A61K41/00 , A61K33/00 , A61K33/04 , A61K33/06 , A61K33/28 , A61K35/02 , A61K35/58 , A61K35/646 , A61K36/185 , A61K45/06 , A61K35/583
摘要： The present invention is directed to a homeopathic complex for use in the treatment of various diseases or disorders, including use as an anti-infective agent and/or in the regeneration of diseased or damaged tissue. Ideally, the anti-infective homeopathic complex of the invention may comprise a homeopathic tincture or dilutions thereof of Hepar sulphuris calcareum or other similar profiled Calcarea or Sulphur salt or acid, Lachesis muta or other remedy with a similar profile, Mercurius Solubilis or similar mercury containing remedy and Silica or other silica containing compounds.

3. 发明授权

US11007147B2 Hydrogel toxin-absorbing or binding nanoparticles 有权
公开(公告)号：US11007147B2
公开(公告)日：2021-05-18
申请号：US16811515
申请日：2020-03-06
申请人： The Regents of the University of California
发明人： Liangfang Zhang , Che-Ming Jack Hu , Weiwei Gao , Jonathan Copp
IPC分类号： A61K9/06 , A61K9/16 , A61K9/51 , A61K38/17 , A61K35/17 , A61K35/18 , A61K35/19 , A61K35/58 , A61K35/63 , A61K45/06 , A61K31/49 , A61L26/00 , A61K9/00 , A61L27/52 , A61L27/54 , A61K9/50
摘要： The present invention provides for compositions comprising a polymeric hydrogel impregnated with a toxin-absorbing or binding nanoparticle. The present invention also provides for the use of the above compositions for decreasing or neutralizing the effect of a toxin, or for treating or preventing an infection by a microbe that produces a toxin, in a subject. The exemplary toxin is a biological toxin such as a viral, bacterial, fungal, plant or animal toxin.

4. 发明授权

US10744165B2 Pharmaceutical composition for preventing and treating cell proliferative disease comprising mixture of feather of birds and scale of fish as an active ingredient 有权
公开(公告)号：US10744165B2
公开(公告)日：2020-08-18
申请号：US15229028
申请日：2016-08-04
申请人： Sang-Moon Lee
发明人： Sang-Moon Lee
IPC分类号： A61K35/57 , A61K35/60 , A61K35/12 , A61K9/00 , A61K35/58
摘要： The present invention relates to a pharmaceutical composition for preventing and treating cell proliferative diseases comprising a feather of birds and a scale of fish, a scale transformed from the dermis, a degenerated or cornified variant of a scale, or a scale or horny scale of reptiles as an active ingredient. More particularly, the present invention relates to a pharmaceutical composition for preventing and treating cell proliferative diseases comprising a mixture of 70˜85 weight % of a feather of birds and 15˜30 weight % of a scale of fish, a scale transformed from the dermis, a degenerated or cornified variant of a scale, or a scale or horny scale of reptiles as an active ingredient. The inventive composition has the effect of inhibiting and preventing growth of cancer cells. Accordingly, the inventive composition may be used for anticancer purposes to prevent, ameliorate or treat cancer.

5. 发明申请

US20120156284A1 ENHANCED BIOLOGICAL AUTOLOGOUS TISSUE ADHESIVE COMPOSITION AND METHODS OF PREPARATION AND USE 审中-公开
标题翻译：增强生物自动组织粘合剂组合物及其制备和使用方法
公开(公告)号：US20120156284A1
公开(公告)日：2012-06-21
申请号：US13407335
申请日：2012-02-28
申请人： Brian D. Burkinshaw , Steven I. Whitlock , James B. Rogan , Gerald L. Devries
发明人： Brian D. Burkinshaw , Steven I. Whitlock , James B. Rogan , Gerald L. Devries
IPC分类号： A61K38/36 , A61K39/395 , A61K38/21 , A61K9/127 , A61P7/04 , A61P29/00 , A61P23/00 , A61P31/00 , A61P7/02 , A61P31/10 , A61P9/00 , A61P35/00 , A61P19/08 , A61P19/04 , A61P3/02 , A61K35/58
CPC分类号： A61L24/106 , A61K35/58 , A61K38/363 , A61K45/06 , A61K2300/00
摘要： The invention includes a composition useful for preparing a tissue sealant for use on a patient, comprising: autologous fibrinogen, an activating agent and at least one supplement. The invention includes a method of treating a disc having at least one defect, comprising: introducing a composition into the disc, wherein the composition comprises autologous fibrinogen and an activating agent, and wherein the composition forms fibrin.
摘要翻译：本发明包括可用于制备用于患者的组织密封剂的组合物，其包含：自体纤维蛋白原，活化剂和至少一种补充物。本发明包括治疗具有至少一个缺损的椎间盘的方法，包括：将组合物引入椎间盘，其中所述组合物包含自体纤维蛋白原和活化剂，并且其中所述组合物形成纤维蛋白。

6. 发明授权

US5922773A Glaucoma treatment 失效
公开(公告)号：US5922773A
公开(公告)日：1999-07-13
申请号：US984939
申请日：1992-12-04
申请人： Stuart A. Lipton , Evan B. Dreyer
发明人： Stuart A. Lipton , Evan B. Dreyer
IPC分类号： A61K38/16 , A61K31/00 , A61K31/13 , A61K31/195 , A61K31/21 , A61K35/56 , A61K35/58 , A61K38/46 , A61K45/00 , A61K45/08 , A61P3/00 , A61P27/02 , A61P27/06 , A61P43/00 , A61K31/135
CPC分类号： A61K31/00 , Y10S514/912 , Y10S514/913
摘要： Elevated glutamate levels are associated with glaucoma, and damage to retinal ganglion cells can be controlled by administering to the patient a compound capable of reducing glutamate induced excitotoxicity in a concentration effective to cause reduction of such excitotoxicity.

7. 发明授权

US5676974A Pharmaceutical compositions containing giroxina and phospholipase A.sub.2 and methods of increasing a patient's CD.sub.4 count using the pharmaceutical compositions 失效
标题翻译：含有吉西菌素和磷脂酶A2的药物组合物和使用药物组合物增加患者CD4计数的方法
公开(公告)号：US5676974A
公开(公告)日：1997-10-14
申请号：US340424
申请日：1994-11-15
申请人： Santiago H. Valdes , Diego Jose Carpintero
发明人： Santiago H. Valdes , Diego Jose Carpintero
IPC分类号： A61K38/46 , A61K35/58 , C12N9/20
CPC分类号： A61K38/1703 , A61K38/465 , C12Y301/01004
摘要： Pharmaceutical compositions for treatment of humans suffering from the symptoms of acquired immune deficiency syndrome (AIDS) or its precursors, lymphadenopathy syndrome (LAS) or AIDS-related complex (ARC) or secondary diseases relating thereto and other immunodeficiency pathologies or tumors resulting exclusively from immune deficiency and others such as H.I.V. The compositions contain a therapeutically active amount of phospholipase A.sub.2 and giroxina, preferably where the phospholipase A.sub.2 is isolated from the venom of Crotalus durissus terrificus or form the venom of Micrurus frontalis altirostris and the giroxina is isolated from the venom of Crotalus durissus terrificus. Also disclosed is the process for preparing such pharmaceutical composition and the process for treating patients suffering from the aforementioned afflictions.
摘要翻译：用于治疗患有获得性免疫缺陷综合征（AIDS）或其前体，淋巴结病综合征（LAS）或AIDS相关综合征（ARC）或与其相关的继发性疾病的症状的人的药物组合物和其他免疫缺陷病症或肿瘤缺乏症等艾滋病毒组合物含有治疗活性量的磷脂酶A2和吉西他宁，优选地，其中磷脂酶A2是从龙胆的毒液中分离出来的，或者形成了前额叶甲的毒液，并且从罗勒龙属的毒液中分离出吉罗尼菌。还公开了制备这种药物组合物的方法和用于治疗患有上述苦难的患者的方法。

8. 发明授权

US5066593A Synthetic peptide-based anti-rabies compositions and methods 失效
标题翻译：基于合成肽的抗狂犬病药物组合物和方法
公开(公告)号：US5066593A
公开(公告)日：1991-11-19
申请号：US91509
申请日：1987-08-31
申请人： James W. Patrick , Stephen F. Heinemann , Barbara D. Boss , W. Maxwell Cowan
发明人： James W. Patrick , Stephen F. Heinemann , Barbara D. Boss , W. Maxwell Cowan
IPC分类号： A61K35/58 , A61K39/00 , A61K39/205 , A61K39/395 , A61K39/42 , C07K14/145 , C07K16/10 , G01N33/569
CPC分类号： C07K14/005 , A61K35/58 , A61K39/12 , A61K39/205 , A61K39/395 , A61K39/42 , C07K16/10 , G01N33/56983 , A61K2039/55566 , A61K2039/6081 , C12N2760/20122 , C12N2760/20134
摘要： A sequence in the coat glycoprotein of rabies virus is identified as the molecular basis for an essential step in the pathogenesis of the virus, the binding of virus to acetylcholine receptor at neuromuscular junctions prior to virus uptake into peripheral nerves. Based on this discovery, synthetic peptide-based, anti-rabies vaccines are prepared. The active ingredient of such vaccines is a synthetic protein, which is a conjugate with an immunogenic carrier protein of a synthetic peptide with a sequence which includes a sequence which is substantially the same as a substantial portion of the sequence of the acetylcholine receptor-binding segment of the rabies virus coat protein. Anti-rabies antisera, and anti-rabies antibodies, are prepared by injecting a mammal with a synthetic protein of the invention in a manner that induces an immune response in the mammal against the synthetic protein. Hybridomas which secrete anti-rabies antibodies, which bind to specific epitopes on or near the acetylcholine receptor binding segment on the rabies virus coat glycoprotein, are prepared with B cells immunized in vitro with a synthetic peptide or synthetic protein of the invention or taken from a mammal inoculated with such a peptide or protein. The anti-rabies vaccines of the invention avoid risks associated with currently available anti-rabies vaccines. The antisera and antibodies of the invention are useful therapeutically to induce passive anti-rabies immunity in a mammal that has been exposed to rabies virus. The antisera and antibodies are also useful for diagnosing whether a mammal is rabid and whether a mammal has been exposed to live rabies virus.
摘要翻译：鉴定狂犬病病毒外壳糖蛋白中的序列是病毒发病机理中必不可少的步骤的分子基础，在病毒摄入到外周神经之前，病毒与神经肌肉接头处的乙酰胆碱受体结合。基于这一发现，制备合成的基于肽的抗狂犬病疫苗。这种疫苗的活性成分是合成蛋白质，其是具有合成肽的免疫原性载体蛋白的缀合物，其具有序列，其包含与乙酰胆碱受体结合区段的大部分基本相同的序列的狂犬病病毒外壳蛋白。抗狂犬病抗血清和抗狂犬病抗体通过以对哺乳动物诱导针对合成蛋白质的免疫应答的方式向哺乳动物注射本发明的合成蛋白质来制备。使用与本发明的合成肽或合成蛋白质体外免疫的B细胞一起制备分泌抗狂犬病抗体的杂交瘤，其与狂犬病病毒外壳糖蛋白上的乙酰胆碱受体结合片段上或附近的特异性表位结合，用这种肽或蛋白质接种的哺乳动物。本发明的抗狂犬病疫苗避免了与目前可用的抗狂犬病疫苗相关的风险。本发明的抗血清和抗体可用于在暴露于狂犬病病毒的哺乳动物中诱导被动抗狂犬病免疫。抗血清和抗体也可用于诊断哺乳动物是否狂犬病以及哺乳动物是否已经暴露于活狂犬病毒。

9. 发明授权

US4741902A Compositions for treatment of neurological and related disorders 失效
标题翻译：用于治疗神经系统和相关疾病的组合物
公开(公告)号：US4741902A
公开(公告)日：1988-05-03
申请号：US885091
申请日：1986-07-14
申请人： William E. Haast
发明人： William E. Haast
IPC分类号： A61K35/58 , A61K39/00
CPC分类号： A61K35/58 , Y10S514/825 , Y10S514/885 , Y10S514/903 , Y10S514/907
摘要： The invention provides compositions of matter having pharmacological activity and which are useful in the treatment of the symptoms of neurological and other disorders, particularly those disorders which are caused by malfunction of the immune mechanism. The present compositions include venoms and/or venom fractions extracted from various elapid and viperid snakes and generally include a postsynaptic component capable of binding to nicotinic acetylcholine receptors of cells, a presynaptic component capable of inhibition of acetylcholine release, and a viperid component stimulative of the immune system. According to the present invention, the viperid component of the present compositions of matter preferably constitutes a venom fraction which is absent certain enzymes such as L-amino acid oxidase and phosphodiesterase, these compositions being of particular utility due to the absence of a hemorrhagic effect when used in the treatment of mammals. Methods of preparation and use of the present compositions of matter are also disclosed.
摘要翻译：本发明提供了具有药理学活性的物质的组合物，其可用于治疗神经系统疾病和其它疾病的症状，特别是那些由免疫机制的功能障碍引起的疾病。本发明的组合物包括从各种elapid和viperid蛇提取的毒液和/或毒液馏分，并且通常包括能够结合细胞的烟碱乙酰胆碱受体的突触后成分，能够抑制乙酰胆碱释放的突触前成分，以及刺激免疫系统。根据本发明，本发明组合物的恶臭组分优选构成没有某些酶如L-氨基酸氧化酶和磷酸二酯酶的毒液组分，这些组合物由于不存在出血效应而特别有用，因为当用于哺乳动物的治疗。还公开了本发明组合物的制备和使用方法。

10. 发明授权

US4707356A Synthetic peptide-based anti-rabies compositions and methods 失效
公开(公告)号：US4707356A
公开(公告)日：1987-11-17
申请号：US941163
申请日：1986-12-12
申请人： James W. Patrick , Stephen F. Heinemann , Barbara D. Boss , W. Maxwell Cowan
发明人： James W. Patrick , Stephen F. Heinemann , Barbara D. Boss , W. Maxwell Cowan
IPC分类号： A61K35/58 , A61K39/00 , A61K39/205 , A61K39/395 , A61K39/42 , C07K14/145 , C07K16/10 , G01N33/569 , A61K37/02
CPC分类号： C07K14/005 , A61K35/58 , A61K39/12 , A61K39/205 , A61K39/395 , A61K39/42 , C07K16/10 , G01N33/56983 , A61K2039/55566 , A61K2039/6081 , C12N2760/20122 , C12N2760/20134
摘要： A sequence in the coat glycoprotein of rabies virus is identified as the molecular basis for an essential step in the pathogenesis of the virus, the binding of virus to acetylcholine receptor at neuromuscular junctions prior to virus uptake into peripheral nerves. Based on this discovery, synthetic peptide-based, anti-rabies vaccines are prepared. The active ingredient of such vaccines is a synthetic protein, which is a conjugate with an immunogenic carrier protein of a synthetic peptide with a sequence which includes a sequence which is substantially the same as a substantial portion of the sequence of the acetylcholine receptor-binding segment of the rabies virus coat protein. Anti-rabies antisera, and anti-rabies antibodies, are prepared by injecting a mammal with a synthetic protein of the invention in a manner that induces an immune response in the mammal against the synthetic protein. Hybridomas which secrete anti-rabies antibodies, which bind to specific epitopes on or near the acetylcholine receptor binding segment on the rabies virus coat glycoprotein, are prepared with B cells immunized in vitro with a synthetic peptide or synthetic protein of the invention or taken from a mammal inoculated with such a peptide or protein. The anti-rabies vaccines of the invention avoid risks associated with currently available anti-rabies vaccines. The antisera and antibodies of the invention are useful therapeutically to induce passive anti-rabies immunity in a mammal that has been exposed to rabies virus. The antisera and antibodies are also useful for diagnosing whether a mammal is rabid and whether a mammal has been exposed to live rabies virus.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式